🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

7,888 results for “1” Clear

  1. SB11 (Proposed ranibizumab biosimilar)

    Samsung Bioepis NL B.V.

    Age-Related Macular Degeneration

    phase 3 small molecule completed

    1 trial

  2. SC treatment with IGSC, 10% with rHuPH20 followed by SC/IGSC, 10% only (safety)

    Takeda

    Primary Immunodeficiency Diseases (PID)

    phase 3 mab completed

    1 trial

  3. SCENESSE 16 mg implant

    Clinuvel Europe Limited

    Vitiligo

    phase 3 small molecule active

    1 trial

  4. SECUKINUMAB

    Novartis Pharmaceuticals

    Polymyalgia Rheumatica

    phase 3 small molecule active

    1 trial

  5. SEG101

    Novartis Pharmaceuticals

    Sickle cell disease

    phase 3 small molecule active

    1 trial

  6. SELINEXOR, Selinexor placebo for 20 mg tablets is formulated for oral administration. selinexor placebo tablets are film coated bi-convex round tablets

    Karyopharm Therapeutics Inc

    endometrial cancer

    phase 3 small molecule active

    1 trial

  7. SELUMETINIB, SELUMETINIB, Placebo to match Selumetinib capsules, 10 and 25 mg.

    AstraZeneca AB

    Neurofibromatosis Type 1 (NF1) with Symptomatic, Inoperable Plexiform Neurofibromas (PN).

    phase 3 small molecule active

    1 trial

  8. SER-109

    Seres Therapeutics

    Clostridioides Difficile Infection

    phase 3 mab completed

    1 trial

  9. SER-109

    Seres Therapeutics

    Clostridium Difficile Infection

    phase 3 mab completed

    1 trial

  10. SGM-101

    BRIGHT MINDS BIOSCIENCES INC.

    Rectal Cancer

    phase 3 small molecule active

    1 trial

  11. SHP465 12.5mg capsules (one capsule daily)

    Takeda

    Attention Deficit Hyperactivity Disorder (ADHD)

    phase 3 small molecule completed

    1 trial

  12. SHP615

    Takeda

    Nervous System Diseases

    phase 3 small molecule completed

    2 trials

  13. SHP615

    Shire

    Nervous System Diseases

    phase 3 small molecule completed

    1 trial

  14. SHR-1210

    Jian Li

    Locally Advanced or Metastatic and Unresectable HCC

    phase 3 small molecule completed

    1 trial

  15. SMC021 Oral Calcitonin

    Nordic Bioscience A/S

    Osteoarthritis

    phase 3 small molecule completed

    1 trial

  16. SMC021 Oral calcitonin

    Nordic Bioscience A/S

    Osteoporosis

    phase 3 small molecule completed

    1 trial

  17. SOC plus 15mg/kg EB05 IV

    Edesa Biotech

    COVID-19

    phase 3 mab on hold

    1 trial

  18. SODIUM CHLORIDE , CAEL-101

    Alexion Europe SAS

    stage IIIa cardiac AL amyloidosis

    phase 3 small molecule active

    1 trial

  19. SODIUM CHLORIDE , CAEL-101

    Alexion Europe SAS

    Stage IIIb cardiac AL amyloidosis

    phase 3 small molecule active

    1 trial

  20. SODIUM CHLORIDE , DYNE-101

    Dyne Therapeutics

    Myotonic Dystrophy Type 1

    phase 3 small molecule active

    1 trial

  21. SODIUM CHLORIDE, HYDROCORTISONE UPJOHN 100 mg, préparation injectable, Placebo of hydrocortisone 100 mg, Reverpleg 40 U.I./2 ml solution à diluer pour perfusion

    Pari Pharma GmbH

    Adult cardiac arrest patients with sustained ROSC and hemodynamic failure due to post-resuscitation syndrome

    phase 3 small molecule active

    1 trial

  22. SODIUM CHLORIDE, Kineret 100 mg/0.67 ml solution for injection in pre-filled syringe.

    Pari Pharma GmbH

    PEDIATRIC ACUTE MYOCARDITIS

    phase 3 small molecule active

    1 trial

  23. SODIUM CHLORIDE, LEVETIRACETAM VIATRIS 100 mg/ml, solution à diluer pour perfusion

    Pari Pharma GmbH

    Adult ICU patients with septic shock

    phase 3 small molecule active

    1 trial

  24. SODIUM CHLORIDE, MYCOPHENOLATE MOFETIL, GLUCOSE, Oleclumab, MYCOPHENOLATE MOFETIL, IMFINZI 50 mg/mL concentrate for solution for infusion., Monalizumab, IMFINZI 50 mg/mL concentrate for solution for infusion., INFLIXIMAB

    AstraZeneca AB

    Patients With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources